Syngene International Limited (SYNGENE.BO)
- Previous Close
698.95 - Open
691.80 - Bid 699.45 x --
- Ask 698.45 x --
- Day's Range
685.85 - 704.90 - 52 Week Range
660.35 - 860.20 - Volume
29,097 - Avg. Volume
23,014 - Market Cap (intraday)
280.203B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
54.94 - EPS (TTM)
12.71 - Earnings Date Jul 24, 2024 - Jul 29, 2024
- Forward Dividend & Yield 1.25 (0.18%)
- Ex-Dividend Date Jun 28, 2024
- 1y Target Est
622.00
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, Japan, Europe, the United States, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, clinical data management, regulatory, biostatistics, and medical writing services. Further, it offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
www.syngeneintl.comRelated News
Performance Overview: SYNGENE.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYNGENE.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYNGENE.BO
Valuation Measures
Market Cap
280.20B
Enterprise Value
274.78B
Trailing P/E
55.02
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.04
Price/Book (mrq)
6.58
Enterprise Value/Revenue
7.88
Enterprise Value/EBITDA
25.12
Financial Highlights
Profitability and Income Statement
Profit Margin
14.62%
Return on Assets (ttm)
6.72%
Return on Equity (ttm)
12.95%
Revenue (ttm)
34.89B
Net Income Avi to Common (ttm)
5.1B
Diluted EPS (ttm)
12.71
Balance Sheet and Cash Flow
Total Cash (mrq)
10.77B
Total Debt/Equity (mrq)
13.04%
Levered Free Cash Flow (ttm)
4.54B
Research Analysis: SYNGENE.BO
Company Insights: SYNGENE.BO
SYNGENE.BO does not have Company Insights